In-hospital mortality associated with necrotizing soft tissue infection due to Vibrio vulnificus: a matched-pair cohort study

Chih-Yao Chang¹, Kai-Hsiang Wu¹, Po-Han Wu¹, Shang-Kai Hung², Cheng-Ting Hsiao¹³, Shu-Ruei Wu⁴ and Chia-Peng Chang¹*

Abstract

Background: It remains unclear whether Vibrio vulnificus necrotizing soft tissue infection (NSTI) is associated with higher mortality compared with non-Vibrio NSTI. This study's objective was to compare outcomes including in-hospital mortality and prognosis between patients with V. vulnificus NSTI and those with non-Vibrio NSTI.

Method: A retrospective 1:2 matched-pair cohort study of hospitalized patients with NSTI diagnosed by surgical finding was conducted in two tertiary hospitals in southern Taiwan between January 2015 and January 2020. In-hospital outcomes (mortality, length of stay) were compared between patients with and without V. vulnificus infection. We performed multiple imputation using chained equations followed by multivariable regression analyses fitted with generalized estimating equations to account for clustering within matched pairs. All-cause in-hospital mortality and length of stay during hospitalization were compared for NSTI patients with and without V. vulnificus.

Result: A total of 135 patients were included, 45 in V. vulnificus NSTI group and 90 in non-Vibrio group. The V. vulnificus NSTI patients had higher mortality and longer hospital stays. Multivariable logistic regression analysis revealed that V. vulnificus NSTI was significantly associated with higher in-hospital mortality compared with non-Vibrio NSTI (adjusted odds ratio = 1.52; 95% confidence interval 1.36–1.70; p < 0.01).

Conclusion: Vibrio vulnificus NSTI was associated with higher in-hospital mortality and longer hospital stay which may increase health care costs, suggesting that preventing V. vulnificus infection is essential.

Keywords: Necrotizing soft tissue infection, Mortality, Vibrio vulnificus

Introduction

Necrotizing soft tissue infection (NSTI) is a severe, rapidly progressive disease that is characterized by the infection of subcutaneous tissue and fascia, resulting in extensive fascial necrosis [1]. The gold standard management for NSTI is rapid debridement and broad-spectrum antibiotics [2]. Even under rapid and timely management, the risk of mortality and morbidity, such as amputation and multiorgan dysfunction, remains high [3–5]. NSTI caused by Vibrio vulnificus is a life-threatening condition with rapid progression and high mortality. It usually occurs through the injuries sustained when handling seafood, wound exposure to seawater, and ingestion of contaminated under-cooked seafood. Immunocompromised patients are also at higher risk of developing this disease [6–8].

Mortality from NSTI caused by gram-negative pathogens has been reported to be higher than caused by other pathogens in warm costal area [9]; however, it remains
unclear whether mortality from *V. vulnificus* NSTI is higher than mortality from non-*Vibrio* NSTI. Only a few studies have compared mortality between *V. vulnificus* NSTI and non-*Vibrio* NSTI; one showed that the clinical features of *V. vulnificus* infection were more rapidly progressive and fulminant than those of the methicillin-resistant *Staphylococcus aureus* (MRSA) or MSSA infection [10], whereas another showed that the laboratory risk indicator for necrotizing fasciitis (LRINEC) score was inaccurate in necrotizing fasciitis caused by *V. vulnificus*. [11]. The aim of the present study was to examine the differences in in-hospital mortality between patients with *V. vulnificus* NSTI and those with non-*Vibrio* NSTI, adjusting for comorbidities.

**Material and methods**

**Patient selection**

Under the approval of institutional review board, a retrospective cohort study was conducted. The medical records of patients who met the inclusion criteria of surgically proven NSTI and who received management between 2015 and 2020 in two tertiary hospitals were reviewed. Among the patients with NSTI, we selected *V. vulnificus* group and non-*Vibrio* group with 1:2 matching. For each patient in the *V. vulnificus* group, we identified two non-*Vibrio* patients of the same sex who were admitted to the same hospital in the same year and whose ages were within 5 years of the age of the *V. vulnificus* patient. We defined *V. vulnificus* NSTI group as blood culture or surgical wound culture yields *V. vulnificus*, or both yield *V. vulnificus*.

**Data collection and analysis**

Age, sex, vital signs in the emergency department (ED), hospital stay, the presence of comorbidities, and blood biochemistry profile were analyzed. After data collection was completed, random chart reviews were performed to ensure accuracy. We used hospital identifiers for matching to cancel out site-specific effects such as physician practice patterns and treatment outcomes. We performed multiple imputation for missing data on systolic blood pressure, body temperature, heart rate, and biochemistry analysis of blood. We replaced each missing value with a set of substituted plausible values by generating multiple datasets using the multivariate imputation by chained equations method. The following covariates were used to create these 10 complete datasets: *V. vulnificus* NSTI, age, sex, comorbidity, seawater or seafood contact, serum lactate, LRINEC (laboratory risk indicator for necrotizing fasciitis) score, in-hospital death, and 30-day in-hospital death, with the assumption that data were missing at random. Estimates from these imputed datasets were combined using Rubin’s rule to obtain combined imputation estimates and standard errors. Then, using multivariable logistic regression analysis fitted with generalized estimating equations to account for the 1:2 matched-pair clustering, we examined the factors associated with all-cause in-hospital mortality.

**Outcomes**

The primary outcome of this study was all-cause in-hospital mortality. The secondary outcomes were 30-day in-hospital mortality and length of stay.

**Statistical analysis**

All data were analyzed using the Statistical Package for the Social Sciences software, version 20.0 (IBM Corp., Armonk, NY, USA). The chi-square test was used to compare proportions between groups. The two-sample *t* test was used to compare average values, and the Mann–Whitney test was used to compare the median values between groups. Using multivariable logistic regression analysis fitted with generalized estimating equations to account for the 1:2 matched-pair clustering, we examined the factors associated with all-cause in-hospital mortality. Multiple linear regression analysis fitted with generalized estimating equations.

**Results**

A total of 135 patients were included, 45 in *V. vulnificus* NSTI group and 90 in non-*Vibrio* group. The mean age was 69.3 years (standard deviation [SD] = 12.7), and 66.4% of the patients were male. Table 1 shows the characteristics of patients with *V. vulnificus* NSTI and non-*Vibrio* NSTI after 1:2 matching. The *V. vulnificus* NSTI group tended to have hypotension, bacteremia, history of seawater or seafood contact, comorbidity with liver disease, and higher serum lactate. All-cause in-hospital mortality was 13.3% in the *V. vulnificus* NSTI, whereas it was 7.8% in the non-*Vibrio* NSTI (Table 2). All-cause 30-day was also higher in the *V. vulnificus* NSTI than in the non-*Vibrio* group. Length of hospital stay was longer in the *V. vulnificus* NSTI than in the non-*Vibrio* group. Table 3 shows the results of the multivariable logistic regression analysis with generalized estimating equations after multiple imputation for all-cause in-hospital mortality. *V. vulnificus* NSTI was significantly associated with higher mortality compared with non-*Vibrio* group (adjusted odds ratio = 1.52; 95% confidence interval 1.36–1.70; *p* < 0.01). Higher mortality was significantly associated with higher serum lactate, higher LRINEC score, and with liver disease.


**Table 1** Clinical characteristics between *V. vulnificus* and non-*Vibrio* groups

| Variables                                | *V. vulnificus* group | Non-*Vibrio* group | *P* value |
|------------------------------------------|-----------------------|--------------------|-----------|
| Age (years, mean ± SD)                   | 69.1 ± 12.8           | 69.4 ± 12.5        | 0.82      |
| Sex (male)                               | 29 (64.4%)            | 58 (64.4%)         | 0.99      |
| Systolic blood pressure < 90 mmHg       | 10 (22.2%)            | 7 (17.7%)          | 0.02*     |
| Heart rate ≥ 100/min                     | 24 (53.3%)            | 44 (48.9%)         | 0.59      |
| Body temperature > 38 °C                | 11 (24.4%)            | 23 (25.6%)         | 0.38      |
| Malignancy                               | 3 (6.7%)              | 5 (5.6%)           | 0.63      |
| Heart disease                            | 7 (15.6%)             | 12 (13.3%)         | 0.57      |
| Liver disease                            | 19 (42.2%)            | 28 (31.1%)         | < 0.03*   |
| Kidney disease                           | 13 (28.9%)            | 23 (25.6%)         | 0.72      |
| Peripheral vascular disease              | 4 (8.9%)              | 7 (17.7%)          | 0.41      |
| Diabetes mellitus                        | 12 (26.7%)            | 26 (28.9%)         | 0.28      |
| Presence of bacteremia                   | 29 (64.4%)            | 19 (21.1%)         | < 0.01*   |
| Seawater or seafood contact              | 40 (88.9%)            | 11 (12.2%)         | < 0.01*   |
| CRP (mg/L) (mean)                        | 70.1 ± 78.9           | 98.6 ± 95.1        | 0.08      |
| WBC (cells/mm³) (mean)                   | 14,870 ± 10,960       | 15,870 ± 9150      | 0.46      |
| Hemoglobin (g/dL) (mean)                 | 12.5 ± 2.12           | 12.1 ± 1.68        | 0.29      |
| Blood glucose (mg/dL) (mean)             | 168 ± 74              | 196 ± 108          | 0.54      |
| Sodium (mmol/L) (mean)                   | 135 ± 2.5             | 136 ± 2.2          | 0.18      |
| Lactate (mg/dL) (mean)                   | 16.3 ± 7.8            | 12.8 ± 10.5        | 0.03*     |
| Creatinine (mg/dL) (mean)                | 1.58 ± 1.15           | 1.32 ± 0.76        | 0.84      |

CRP C-reactive protein, WBC white blood cell

*P < 0.05

**Table 2** Outcomes of patients with *V. vulnificus* and non-*Vibrio* after 1:2 matching

|                  | *V. vulnificus* group | Non-*Vibrio* group | *P* value |
|------------------|-----------------------|--------------------|-----------|
| In-hospital mortality | 6 (13.3%)            | 7 (7.8%)           | < 0.01*   |
| 30-day mortality      | 5 (11.1%)            | 5 (5.6%)           | < 0.01*   |
| Length of hospital stay (days) | 28 (18–46) | 20 (14–53) | 0.02* |

Data are expressed as numbers (%) or as medians [interquartile ranges]

*P < 0.05

**Discussion**

*Vibrio vulnificus* is a gram-negative marine bacterium that is usually present in warm coastal waters. The main clinical manifestations of *V. vulnificus* infections in humans are gastrointestinal illnesses, primary septicaemia, and wound infections. The clinical course can progress rapidly by releasing hemolysins and proteases and result in hemorrhagic bullae and severe skin necrosis [10, 12, 13]. The routes of necrotizing soft tissue infection caused by *V. vulnificus* include wound infections while handling seafood, exposure of a preexisting wound to seawater, and ingestion of contaminated under-cooked seafood [12–14].

Using two tertiary hospital database in Southern Taiwan, our study showed that mortality was higher in patients with *V. vulnificus* NSTI than those in non-*Vibrio* group. In our study, in-hospital mortality among patients with *V. vulnificus* NSTI was 13.3%. Previous studies have reported *vulnificus* NSTI mortality around 10–13% [9, 15], which is comparable to our results. Mortality from NSTI caused by gram-negative or monomicrobial pathogen has been reported to be higher than caused by other pathogens. Namany et al. [16] found that monomicrobial disease group had a significantly higher 90-day mortality rate in addition to higher rates of in-hospital mortality, ICU admission, and vasopressor use than the polymicrobial disease group. Huang et al. [17] revealed that NSTI caused by monomicrobial *Aeromonas* spp. revealed high mortality rates, even through aggressive surgical debridement and antibacterial therapies. They all raised concern...
for increasing risk of monomicrobial infection and gram-negative pathogen. As comparison, the non-Vibrio group are including gram-positive, negative, and culture no growth patients, and possibly monomicrobial or polymicrobial. Mainly pathogens included Aeromonas spp., Pseudomonas, Escherichia coli, Klebsiella pneumoniae, Staphylococcus, and Streptococcus spp. (There are 39 monomicrobial gram-positive, 10 monomicrobial negative, 15 polymicrobial, and 26 culture no growth in non-Vibrio group in our data.)

In V. vulnificus NSTI, there are 17 patients with positive blood and wound culture (26.7%), and 16 patients with positive wound culture (35.5%). In non-Vibrio group, there are 19 patients with bacteremia (21.1%). V. vulnificus group had higher incidence of bacteremia than non-Vibrio group (64.4% vs 21.1%). Tsai et al. conducted a study about NSTI patients with V. vulnificus and methicillin-resistant Staphylococcus aureus (MRSA). The incidence of bacteremia was 65% vs 18.75%; V. vulnificus group was also higher than MRSA group [9]. Immune-compromised and chronic liver disease (chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma) patients with V. vulnificus are more likely to develop blood stream infections [6, 18, 19]. In our study, the incidence of chronic liver disease was also higher in V. vulnificus group. Vibrio vulnificus can produce Vibrio vulnificus hemolysin/cytolysin (Vvh), multifunctional autoprocessing RTX toxin, Vibrio vulnificus serine protease (VvsA), and Vibrio vulnificus protease (VVP). Both Vvh and RTX toxin contribute to bacterial invasion to the blood stream and play a role in the development of hypotensive septic shock. The RTX toxin may promote the colonization at

|                  | Adjusted odds ratio | 95% confidence interval | P value |
|------------------|---------------------|-------------------------|---------|
| V. vulnificus NSTI | 1.52                | 1.36–1.70               | <0.01*  |
| Age (years)      | 1.01                | 1.00–1.01               | <0.01*  |
| Sex (male)       | 0.59                | 0.52–0.67               | 0.36    |
| Liver disease    | 1.42                | 1.08–1.87               | <0.01*  |
| Kidney disease   | 0.95                | 0.68–1.32               | 0.74    |
| Seawater or seafood contact | 1.40     | 1.01–1.97               | <0.01*  |
| Lactate > 18 mg/dL | 1.59              | 1.07–2.38               | <0.01*  |
| Lactate ≤ 18 mg/dL | 1.09              | 0.72–1.63               | 0.48    |
| LRINEC score > 8 | 1.84                | 1.54–2.20               | <0.01*  |
| LRINEC score ≤ 8 | 1.05                | 0.80–1.37               | 0.69    |

*P<0.05
Fourth, the degree of liver disease in each group is not clearly stated.

**Conclusions**

In summary, adjusted in-hospital mortality was significantly higher for patients with *V. vulnificus* NSTI than for those with non-*Vibrio* NSTI in this matched-pair cohort study. Preventing *V. vulnificus* infection is essential. The validity of the result still needs to be confirmed by further studies.

**Abbreviations**

CRP: C-reactive protein; ED: Emergency department; Hb: Hemoglobin; LRINEC: Laboratory risk indicator for necrotizing fasciitis; MRSA: Methicillin-resistant *Staphylococcus aureus*; NSTI: Necrotizing soft tissue infection; OR: Odds ratio; SD: Standard deviation; V: *Vibrio* vulnificus; WBC: White blood cell.

**Acknowledgements**

The authors thank all the participants who participated in this study.

**Author contributions**

CYC conceived of the study and participated in its design and coordination and helped to draft the manuscript. CPC, KHW, and SRW participated in drafting the manuscript and statistical analysis. PHW and SKH participated in the design of the study and drafted the manuscript. CTH participated in statistical analysis. All authors read and approved the final manuscript.

**Funding**

The study was supported by Chang Gung Memorial Hospital (CMRPG6E0043) (CMRPG6J0111) (CMRPG6J0112).

**Availability of data and materials**

All the data will be available upon motivated request to the corresponding author of the present paper.

**Declarations**

**Ethics approval and consent to participate**

The institutional review board of Chia-yi Chang Gung Memorial Hospital (IRB number: 100‑41780C0504 and 20190044780C0601) and Kaohsiung Veterans General Hospital (IRB number: VGHKS18‑CT6‑04) and Kaohsiung Veterans General Hospital, Taoyuan, Taiwan. 3 Department of Medicine, Chang Gung University, Taoyuan, Taiwan. 4 Department of Pediatric, Kaohsiung Veterans General Hospital, Taoyuan, Taiwan. 2 Department of Emergency Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan. 3 Department of Medicine, Chang Gung University, Taoyuan, Taiwan. 4 Department of Pediatric, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.

**Received:** 20 March 2022  **Accepted:** 21 May 2022  **Published online:** 27 May 2022

**References**

1. Wong C-H, Chang H-C, Pasupathy S, Khin L-W, Tan J-L, Low C-O. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Jt Surg Am. 2003;85-A:1454–60.

2. Headley AJ. Necrotizing soft tissue infections: a primary care review. Am Fam Phys. 2003;68:323–8.

3. Ozalay M, Ozkoc G, Akpinar S, Hesekli MA, Tandogan RN. Necrotizing soft-tissue infection of a limb: clinical presentation and factors related to mortality. Foot Ankle Int. 2006;27:698–605.

4. Roje Z, Roje Z, Matic D, Librenjak D, Dokuzovic S, Varvodic J. Necrotizing fasciitis: literature review of contemporary strategies for diagnosing and management with three case reports: torso, abdominal wall, upper and lower limbs. World J Emerg Surg. 2011;6:46.

5. Hakkarainen TW, Kopari NM, Pham TN, Evans HL. Necrotizing soft tissue infections: review and current concepts in treatment, systems of care, and outcomes. Curr Prob Surg. 2014;51:344–62.

6. Chang C-P, Hisiao C-T, Lin C-N. Risk factors for mortality in the late amputation of necrotizing fasciitis: a retrospective study. World J Emerg Surg. 2018;13:1–1.

7. Hsu JC, Shen SH, Yang TY, Chen PH, Huang KC, Tsai YH. Necrotizing fasciitis and sepsis caused by *Vibrio vulnificus* and *Klebsiella pneumoniae* in diabetic patients. Biomed J. 2015;38:136–42.

8. Lee YC, Hori LI, Chiu HY, Lee JW, Sheih SJ. Prognostic factor of mortality and its clinical implications in patients with necrotizing fasciitis caused by *Vibrio vulnificus*. Eur J Clin Microbiol Infect Dis. 2014;33:1011–8.

9. Tsai YH, Huang TY, Chen JH, Hisiao CT, Kuo LT, Huang KC. Bacteriology and mortality of necrotizing fasciitis in a tertiary coastal hospital with comparing risk indicators of methicillin-resistant *Staphylococcus aureus* and *Vibrio vulnificus* infections: a prospective study. BMC Infect Dis. 2021;21(1):771.

10. Tsai YH, Wen-Wei Hsu R, Huang KC, Huang TJ. Comparison of necrotizing fasciitis and sepsis caused by *Vibrio vulnificus* and *Staphylococcus aureus*. J Bone Jt Surg Am. 2011;93:274–84.

11. Koh THB, Tan JHJ, Hong CC, Wang W, Nather A. Early clinical manifestations of vibrio necrotising fasciitis. Singap Med J. 2018;59(4):22467.

12. Tsai YH, Hsu RW, Huang TJ, Hsu WH, Huang KC, Li YY, et al. Necrotizing soft tissue infections and sepsis caused by *Vibrio vulnificus* compared with those caused by *Aeromonas* species. J Bone Jt Surg Am. 2007;89:631–6.

13. Chuang YC, Yuan CY, Liu CY, Lan CK, Huang AH. *Vibrio vulnificus* infection in Taiwan: report of 28 cases and review of clinical manifestations and treatment. Clin Infect Dis. 1992;15:271–8.

14. Zhang XH, Austin B. Haemolysins in *Vibrio* species. J Appl Microbiol. 2005;98:1011–9.

15. Hsiao CT, Weng HH, Yuan YD, Chen CT, Chen KC. Predictors of mortality in patients with necrotizing fasciitis. Am J Emerg Med. 2008;26:170–7.

16. Naamany E, Shiber S, Duskin-Bitan H, Yahav D, Bishara J, Sagy I, Granat V.Pathogenetic principles of streptococcal superinfection in necrotizing fasciitis: comparison of clinical, laboratory, radiological, and pathological hallmarks and prognosis. A retrospective analysis. Trauma Surg Acute Care Open. 2021;6(1):e000745. https://doi.org/10.1136/tsaco‑2021‑000745.

17. Huang TY, Peng KT, Hsu WH, Hung CH, Chuang FY, Tsai YH. Independent predictors of mortality for aeromonas necrotizing fasciitis of limbs: an 18-year retrospective study. Sci Rep. 2020;10(1):7716. https://doi.org/10.1038/s41598‑020‑64741‑7.

18. Kim JS, Lee EG, Chun BC. Epidemiologic characteristics and case fatality rate of *Vibrio vulnificus* Infection: analysis of 761 cases from 2003 to 2016 in Korea. J Korean Med Sci. 2022;37(9):e79. https://doi.org/10.3346/jkms.2022.37.e79.

19. Wu CJ, Chen PL, Tang HJ, et al. Incidence of *Aeromonas* bacteremia in southern Taiwan: *vibrio* and *Salmonella* bacteremia as comparators. J Microbiol Immunol Infect. 2014;47:145–8.

20. Jeong HG, Satchell KJF. Additive function of *Vibrio vulnificus* MARTXVv and *V. vulnificus* Tsaco‑2021‑000745. J Bone Jt Surg Am. 2022;103(8):s41598‑020‑64741‑7.

21. Lo H, Lin J, Chen Y, et al. RTX toxin enhances the survival of *Vibrio vulnificus* by inhibiting the hemorrhagic damage caused by *Vibrio vulnificus* metalloprotease. Toxicon. 2001;39:1883–6.

22. Elgami A, Miyoshi S. Regulation systems of protease and hemolysin production in *Vibrio vulnificus*. Microbiol Immunol. 2017;61:1–11.

23. Tsai YH, Huang TY, Kuo LT, Chuang PY, Hisiao CT, Huang KC. Comparison of surgical outcomes and predictors in patients with monomicrobial...
necrotizing fasciitis and sepsis caused by Vibrio vulnificus, Aeromonas hydrophila, and Aeromonas sobria. Surg Infect (Larchmt). 2022. https://doi.org/10.1089/sur.2021.337.
25. Hsu JC, Shen SH, Yang TY, Chen PH, Huang KC, Tsai YH. Necrotizing fasciitis and sepsis caused by Vibrio vulnificus and Klebsiella pneumoniae in diabetic patients. Biomed J. 2015;38(2):136–42. https://doi.org/10.4103/2319-4170.137767.
26. Chang CP, Hsiao CT, Fann WC. Risk factors associated with bacteremia correlated with mortality in patients with acute bacterial skin and skin structure infection. Intern Emerg Med. 2019;14(2):259–64.
27. Lee CY, Kuo LT, Peng KT, Hsu WH, Huang TW, Chou YC. Prognostic factors and monomicrobial necrotizing fasciitis: gram-positive versus gram-negative pathogens. BMC Infect Dis. 2011;11(5). https://doi.org/10.1186/1471-2334-11-5.
28. Wu PH, Wu KH, Hsiao CT, Wu SR, Chang CP. Utility of modified laboratory risk indicator for necrotizing fasciitis (MLRINEC) score in distinguishing necrotizing from non-necrotizing soft tissue infections. World J Emerg Surg. 2021;16(1):26. https://doi.org/10.1186/s13017-021-00373-0.
29. Bair MJ, Chi H, Wang WS, Hsiao YC, Chiang RA, Chang KY. Necrotizing fasciitis in southeast Taiwan: clinical features, microbiology, and prognosis. Int J Infect Dis. 2009;13(2):255–60. https://doi.org/10.1016/j.ijid.2008.04.015.
30. Chang CP, Fann WC, Wu SR, et al. Lactate on emergency department arrival as a predictor of in-hospital mortality in necrotizing fasciitis: a retrospective study. J Orthop Surg Res. 2019;14:73.
31. Wu KH, Wu PH, Chang CY, Kuo YT, Hsiao KY, Hsiao CT, Hung SK, Chang CP. Differentiating necrotizing soft tissue infections from cellulitis by soft tissue infectious fluid analysis: a pilot study. World J Emerg Surg. 2022;7(1):1. https://doi.org/10.1186/s13017-022-00404-4.
32. Wong CH, Khin LW, Heng KS, Tan KC, Low CO. The LRINEC (laboratory risk indicator for necrotizing fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med. 2004;32(7):1535–41.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.